These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 2121905

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Schapira AH, Mann VM, Cooper JM, Krige D, Jenner PJ, Marsden CD.
    Ann Neurol; 1992; 32 Suppl():S116-24. PubMed ID: 1510369
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease.
    Li H, Shen XM, Dryhurst G.
    J Neurochem; 1998 Nov; 71(5):2049-62. PubMed ID: 9798930
    [Abstract] [Full Text] [Related]

  • 8. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 9. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease.
    Janetzky B, Hauck S, Youdim MB, Riederer P, Jellinger K, Pantucek F, Zöchling R, Boissl KW, Reichmann H.
    Neurosci Lett; 1994 Mar 14; 169(1-2):126-8. PubMed ID: 8047266
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
    Cooper JM, Daniel SE, Marsden CD, Schapira AH.
    Mov Disord; 1995 May 14; 10(3):295-7. PubMed ID: 7651446
    [Abstract] [Full Text] [Related]

  • 16. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW.
    Fortschr Neurol Psychiatr; 1989 Apr 14; 57(4):142-8. PubMed ID: 2656447
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986 Apr 14; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.